Highlights of the 2019 Japanese Society of Hypertension Guidelines and perspectives on the management of Asian hypertensive patients

Satoshi Hoshide; Kazuomi Kario; Naoko Tomitani; Tomoyuki Kabutoya; Yook Chin Chia; Sungha Park; Jinho Shin; Yuda Turana; Jam Chin Tay; Peera Buranakitjaroen; Chen Huan Chen; Jennifer Nailes; Huynh Van Minh; Saulat Siddique; Jorge Sison; Arieska Ann Soenarta; Guru Prasad Sogunuru; Apichard Sukonthasarn; Boon Wee Teo; Narsingh Verma; Yuqing Zhang; Tzung Dau Wang; Ji Guang Wang

doi:10.1111/jch.13763

Highlights of the 2019 Japanese Society of Hypertension Guidelines and perspectives on the management of Asian hypertensive patients

Satoshi Hoshide, Kazuomi Kario, Naoko Tomitani, Tomoyuki Kabutoya, Yook Chin Chia, Sungha Park, Jinho Shin, Yuda Turana, Jam Chin Tay, Peera Buranakitjaroen, Chen Huan Chen, Jennifer Nailes, Huynh Van Minh, Saulat Siddique, Jorge Sison, Arieska Ann Soenarta, Guru Prasad Sogunuru, Apichard Sukonthasarn, Boon Wee Teo, Narsingh VermaYuqing Zhang, Tzung Dau Wang, Ji Guang Wang

Department of Internal Medicine

Research output: Contribution to journal › Review article › peer-review

12 Citations (Scopus)

Abstract

Unlike other international guidelines but in accord with the earlier Japanese Society of Hypertension (JSH) guidelines, the 2019 JSH guidelines (“JSH 2019”) continue to emphasize the importance of out-of-office blood pressure (BP) measurements obtained with a home BP device. Another unique characteristic of JSH 2019 is that it sets clinical questions about the management of hypertension that are based on systematic reviews of updated evidence. JSH 2019 states that individuals with office BP < 140/90 mm Hg do not have normal BP. The final decisions regarding the diagnosis and treatment of hypertension should be performed based on out-of-office BP values together with office BP measurements. For hypertensive adults with comorbidities, the office BP goal is usually <130/80 mm Hg and the home BP goal is <125/75 mm Hg. Recommendations of JSH 2019 would be valuable for not only Japanese hypertensive patients but also Asian hypertensive patients, who share the same features including higher incidence of stroke compared with that of myocardial infarction and a steeper blood pressure-vascular event relationship.

Original language	English
Pages (from-to)	369-377
Number of pages	9
Journal	Journal of Clinical Hypertension
Volume	22
Issue number	3
DOIs	https://doi.org/10.1111/jch.13763
Publication status	Published - 2020 Mar 1

Bibliographical note

Funding Information:
K Kario received research grants from Omron Healthcare, A&D, and Fukuda Denshi Co. Ltd. S Park has received research grants and honoraria from Pfizer. T Kabutoya has received scholarship fund from Mitsubishi Tanabe Pharma Corporation. S Siddique has received honoraria from Bayer, Novartis, Pfizer, ICI, and Servier; and travel, accommodation and conference registration support from Atco Pharmaceutical, Highnoon Laboratories, Horizon Pharma, ICI, Pfizer, and CCL. YC Chia has received honoraria and sponsorship to attend conferences and CME seminars from Abbott, Bayer, Boehringer Ingelheim, GlaxoSmithKline, Menarini, Merck Sharp & Dohme, Novartis, Orient Europharma, Pfizer, and Sanofi; and a research grant from Pfizer. J Shin has received honoraria and sponsorship to attend seminars from Daiichi Sankyo, Takeda, Menarini, MSD, Bristol‐Myers Squibb, and Sanofi. CH Chen has served as an advisor or consultant for Novartis Pharmaceuticals Corporation; has served as a speaker or a member of a speakers bureau for AstraZeneca; Pfizer Inc; Bayer AG; Bristol‐Myers Squibb Company; Boehringer Ingelheim Pharmaceuticals, Inc; Daiichi Sankyo, Inc; Novartis Pharmaceuticals Corporation; SERVIER; Merck & Co., Inc; Sanofi; TAKEDA Pharmaceuticals International; and has received grants for clinical research from Microlife Co., Ltd. J Sison has received honoraria from Pfizer, AstraZeneca, Boehringer Ingelheim, and Novartis. GP Sogunuru has received a research grant related to hypertension monitoring and treatment from Pfizer. JC Tay has received advisory board and consultant honoraria from Pfizer. BW TEO has received honoraria for lectures and consulting fees from Astellas, AstraZeneca, Boehringer Ingelheim, Servier, MSD, and Novartis. TD Wang has served as an advisor for Medtronic and Omron Healthcare; has served as a speaker for Abbott, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Medtronic, Menarini, Novartis, Pfizer, and Sanofi; and has received research grants/support from Abbott, Medtronic, and Novartis. JG Wang has received research grants from Bayer, Merck Sharp & Dohme, Pfizer, and Phillips; and lecture and consulting fees from Bayer, HanHui, Merck, Omron, Salubris, Servier, and Takeda. Y Zhang has received research grants from Bayer, Novartis, and Shuanghe; and lecture fees from Bayer, Daiichi Sankyo, Novartis, Pfizer, Sanofi, Servier, and Takeda. All other authors report no potential conflicts of interest in relation to this article.

Publisher Copyright:
© 2019 Wiley Periodicals, Inc.

All Science Journal Classification (ASJC) codes

Internal Medicine
Endocrinology, Diabetes and Metabolism
Cardiology and Cardiovascular Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/jch.13763

Cite this

Hoshide, S., Kario, K., Tomitani, N., Kabutoya, T., Chia, Y. C., Park, S., Shin, J., Turana, Y., Tay, J. C., Buranakitjaroen, P., Chen, C. H., Nailes, J., Minh, H. V., Siddique, S., Sison, J., Soenarta, A. A., Sogunuru, G. P., Sukonthasarn, A., Teo, B. W., ... Wang, J. G. (2020). Highlights of the 2019 Japanese Society of Hypertension Guidelines and perspectives on the management of Asian hypertensive patients. Journal of Clinical Hypertension, 22(3), 369-377. https://doi.org/10.1111/jch.13763

@article{30c88959f0674df58193cd52a09a8258,

title = "Highlights of the 2019 Japanese Society of Hypertension Guidelines and perspectives on the management of Asian hypertensive patients",

abstract = "Unlike other international guidelines but in accord with the earlier Japanese Society of Hypertension (JSH) guidelines, the 2019 JSH guidelines (“JSH 2019”) continue to emphasize the importance of out-of-office blood pressure (BP) measurements obtained with a home BP device. Another unique characteristic of JSH 2019 is that it sets clinical questions about the management of hypertension that are based on systematic reviews of updated evidence. JSH 2019 states that individuals with office BP < 140/90 mm Hg do not have normal BP. The final decisions regarding the diagnosis and treatment of hypertension should be performed based on out-of-office BP values together with office BP measurements. For hypertensive adults with comorbidities, the office BP goal is usually <130/80 mm Hg and the home BP goal is <125/75 mm Hg. Recommendations of JSH 2019 would be valuable for not only Japanese hypertensive patients but also Asian hypertensive patients, who share the same features including higher incidence of stroke compared with that of myocardial infarction and a steeper blood pressure-vascular event relationship.",

author = "Satoshi Hoshide and Kazuomi Kario and Naoko Tomitani and Tomoyuki Kabutoya and Chia, {Yook Chin} and Sungha Park and Jinho Shin and Yuda Turana and Tay, {Jam Chin} and Peera Buranakitjaroen and Chen, {Chen Huan} and Jennifer Nailes and Minh, {Huynh Van} and Saulat Siddique and Jorge Sison and Soenarta, {Arieska Ann} and Sogunuru, {Guru Prasad} and Apichard Sukonthasarn and Teo, {Boon Wee} and Narsingh Verma and Yuqing Zhang and Wang, {Tzung Dau} and Wang, {Ji Guang}",

note = "Funding Information: K Kario received research grants from Omron Healthcare, A&D, and Fukuda Denshi Co. Ltd. S Park has received research grants and honoraria from Pfizer. T Kabutoya has received scholarship fund from Mitsubishi Tanabe Pharma Corporation. S Siddique has received honoraria from Bayer, Novartis, Pfizer, ICI, and Servier; and travel, accommodation and conference registration support from Atco Pharmaceutical, Highnoon Laboratories, Horizon Pharma, ICI, Pfizer, and CCL. YC Chia has received honoraria and sponsorship to attend conferences and CME seminars from Abbott, Bayer, Boehringer Ingelheim, GlaxoSmithKline, Menarini, Merck Sharp & Dohme, Novartis, Orient Europharma, Pfizer, and Sanofi; and a research grant from Pfizer. J Shin has received honoraria and sponsorship to attend seminars from Daiichi Sankyo, Takeda, Menarini, MSD, Bristol‐Myers Squibb, and Sanofi. CH Chen has served as an advisor or consultant for Novartis Pharmaceuticals Corporation; has served as a speaker or a member of a speakers bureau for AstraZeneca; Pfizer Inc; Bayer AG; Bristol‐Myers Squibb Company; Boehringer Ingelheim Pharmaceuticals, Inc; Daiichi Sankyo, Inc; Novartis Pharmaceuticals Corporation; SERVIER; Merck & Co., Inc; Sanofi; TAKEDA Pharmaceuticals International; and has received grants for clinical research from Microlife Co., Ltd. J Sison has received honoraria from Pfizer, AstraZeneca, Boehringer Ingelheim, and Novartis. GP Sogunuru has received a research grant related to hypertension monitoring and treatment from Pfizer. JC Tay has received advisory board and consultant honoraria from Pfizer. BW TEO has received honoraria for lectures and consulting fees from Astellas, AstraZeneca, Boehringer Ingelheim, Servier, MSD, and Novartis. TD Wang has served as an advisor for Medtronic and Omron Healthcare; has served as a speaker for Abbott, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Medtronic, Menarini, Novartis, Pfizer, and Sanofi; and has received research grants/support from Abbott, Medtronic, and Novartis. JG Wang has received research grants from Bayer, Merck Sharp & Dohme, Pfizer, and Phillips; and lecture and consulting fees from Bayer, HanHui, Merck, Omron, Salubris, Servier, and Takeda. Y Zhang has received research grants from Bayer, Novartis, and Shuanghe; and lecture fees from Bayer, Daiichi Sankyo, Novartis, Pfizer, Sanofi, Servier, and Takeda. All other authors report no potential conflicts of interest in relation to this article. Publisher Copyright: {\textcopyright} 2019 Wiley Periodicals, Inc.",

year = "2020",

month = mar,

day = "1",

doi = "10.1111/jch.13763",

language = "English",

volume = "22",

pages = "369--377",

journal = "Journal of Clinical Hypertension",

issn = "1524-6175",

publisher = "Wiley-Blackwell",

number = "3",

}

Hoshide, S, Kario, K, Tomitani, N, Kabutoya, T, Chia, YC, Park, S, Shin, J, Turana, Y, Tay, JC, Buranakitjaroen, P, Chen, CH, Nailes, J, Minh, HV, Siddique, S, Sison, J, Soenarta, AA, Sogunuru, GP, Sukonthasarn, A, Teo, BW, Verma, N, Zhang, Y, Wang, TD & Wang, JG 2020, 'Highlights of the 2019 Japanese Society of Hypertension Guidelines and perspectives on the management of Asian hypertensive patients', Journal of Clinical Hypertension, vol. 22, no. 3, pp. 369-377. https://doi.org/10.1111/jch.13763

TY - JOUR

T1 - Highlights of the 2019 Japanese Society of Hypertension Guidelines and perspectives on the management of Asian hypertensive patients

AU - Hoshide, Satoshi

AU - Kario, Kazuomi

AU - Tomitani, Naoko

AU - Kabutoya, Tomoyuki

AU - Chia, Yook Chin

AU - Park, Sungha

AU - Shin, Jinho

AU - Turana, Yuda

AU - Tay, Jam Chin

AU - Buranakitjaroen, Peera

AU - Chen, Chen Huan

AU - Nailes, Jennifer

AU - Minh, Huynh Van

AU - Siddique, Saulat

AU - Sison, Jorge

AU - Soenarta, Arieska Ann

AU - Sogunuru, Guru Prasad

AU - Sukonthasarn, Apichard

AU - Teo, Boon Wee

AU - Verma, Narsingh

AU - Zhang, Yuqing

AU - Wang, Tzung Dau

AU - Wang, Ji Guang

N1 - Funding Information: K Kario received research grants from Omron Healthcare, A&D, and Fukuda Denshi Co. Ltd. S Park has received research grants and honoraria from Pfizer. T Kabutoya has received scholarship fund from Mitsubishi Tanabe Pharma Corporation. S Siddique has received honoraria from Bayer, Novartis, Pfizer, ICI, and Servier; and travel, accommodation and conference registration support from Atco Pharmaceutical, Highnoon Laboratories, Horizon Pharma, ICI, Pfizer, and CCL. YC Chia has received honoraria and sponsorship to attend conferences and CME seminars from Abbott, Bayer, Boehringer Ingelheim, GlaxoSmithKline, Menarini, Merck Sharp & Dohme, Novartis, Orient Europharma, Pfizer, and Sanofi; and a research grant from Pfizer. J Shin has received honoraria and sponsorship to attend seminars from Daiichi Sankyo, Takeda, Menarini, MSD, Bristol‐Myers Squibb, and Sanofi. CH Chen has served as an advisor or consultant for Novartis Pharmaceuticals Corporation; has served as a speaker or a member of a speakers bureau for AstraZeneca; Pfizer Inc; Bayer AG; Bristol‐Myers Squibb Company; Boehringer Ingelheim Pharmaceuticals, Inc; Daiichi Sankyo, Inc; Novartis Pharmaceuticals Corporation; SERVIER; Merck & Co., Inc; Sanofi; TAKEDA Pharmaceuticals International; and has received grants for clinical research from Microlife Co., Ltd. J Sison has received honoraria from Pfizer, AstraZeneca, Boehringer Ingelheim, and Novartis. GP Sogunuru has received a research grant related to hypertension monitoring and treatment from Pfizer. JC Tay has received advisory board and consultant honoraria from Pfizer. BW TEO has received honoraria for lectures and consulting fees from Astellas, AstraZeneca, Boehringer Ingelheim, Servier, MSD, and Novartis. TD Wang has served as an advisor for Medtronic and Omron Healthcare; has served as a speaker for Abbott, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Medtronic, Menarini, Novartis, Pfizer, and Sanofi; and has received research grants/support from Abbott, Medtronic, and Novartis. JG Wang has received research grants from Bayer, Merck Sharp & Dohme, Pfizer, and Phillips; and lecture and consulting fees from Bayer, HanHui, Merck, Omron, Salubris, Servier, and Takeda. Y Zhang has received research grants from Bayer, Novartis, and Shuanghe; and lecture fees from Bayer, Daiichi Sankyo, Novartis, Pfizer, Sanofi, Servier, and Takeda. All other authors report no potential conflicts of interest in relation to this article. Publisher Copyright: © 2019 Wiley Periodicals, Inc.

PY - 2020/3/1

Y1 - 2020/3/1

N2 - Unlike other international guidelines but in accord with the earlier Japanese Society of Hypertension (JSH) guidelines, the 2019 JSH guidelines (“JSH 2019”) continue to emphasize the importance of out-of-office blood pressure (BP) measurements obtained with a home BP device. Another unique characteristic of JSH 2019 is that it sets clinical questions about the management of hypertension that are based on systematic reviews of updated evidence. JSH 2019 states that individuals with office BP < 140/90 mm Hg do not have normal BP. The final decisions regarding the diagnosis and treatment of hypertension should be performed based on out-of-office BP values together with office BP measurements. For hypertensive adults with comorbidities, the office BP goal is usually <130/80 mm Hg and the home BP goal is <125/75 mm Hg. Recommendations of JSH 2019 would be valuable for not only Japanese hypertensive patients but also Asian hypertensive patients, who share the same features including higher incidence of stroke compared with that of myocardial infarction and a steeper blood pressure-vascular event relationship.

AB - Unlike other international guidelines but in accord with the earlier Japanese Society of Hypertension (JSH) guidelines, the 2019 JSH guidelines (“JSH 2019”) continue to emphasize the importance of out-of-office blood pressure (BP) measurements obtained with a home BP device. Another unique characteristic of JSH 2019 is that it sets clinical questions about the management of hypertension that are based on systematic reviews of updated evidence. JSH 2019 states that individuals with office BP < 140/90 mm Hg do not have normal BP. The final decisions regarding the diagnosis and treatment of hypertension should be performed based on out-of-office BP values together with office BP measurements. For hypertensive adults with comorbidities, the office BP goal is usually <130/80 mm Hg and the home BP goal is <125/75 mm Hg. Recommendations of JSH 2019 would be valuable for not only Japanese hypertensive patients but also Asian hypertensive patients, who share the same features including higher incidence of stroke compared with that of myocardial infarction and a steeper blood pressure-vascular event relationship.

UR - http://www.scopus.com/inward/record.url?scp=85077889100&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85077889100&partnerID=8YFLogxK

U2 - 10.1111/jch.13763

DO - 10.1111/jch.13763

M3 - Review article

C2 - 31891452

AN - SCOPUS:85077889100

SN - 1524-6175

VL - 22

SP - 369

EP - 377

JO - Journal of Clinical Hypertension

JF - Journal of Clinical Hypertension

IS - 3

ER -

Highlights of the 2019 Japanese Society of Hypertension Guidelines and perspectives on the management of Asian hypertensive patients

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this